Citation:Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, et al 2004

Citation

Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004 Jul 1;22(13):2602-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15226327.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, et al 2004	What is the optimal systemic therapy for stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, et al 2004 2	What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy and who do not have a mutation for targeted therapy?	Dr Margot Lehman MBBS FRANZCR GDP	completed
Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, et al 2004 3	Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, et al 2004 4	What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy?|]] (compare critical appraisals)
• [[Clinical question:Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy and who do not have a mutation for targeted therapy?